Loading stock data…
CBLL
$18.50+0.36 (+1.98%)
After Hours$18.50+0.00 (+0.00%)· Last close Jun 9
CeriBell, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CBLL in the Healthcare sector is trading at $18.50. Wall Street consensus targets $26.86 (7 analysts), implying a +45.2% move over the next 12 months. The stock is currently 24% below its 52-week high of $24.33, remaining 7.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +45.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$18.50
Potential Downside
0%
Whystock Fair Value$18.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.87%
Volume
Today's trading volume
426,208
Recent News
CeriBell Sees ‘Early Innings’ Growth as Hospital Accounts and Usage Hit Records
CeriBell (NASDAQ:CBLL) executives said the company’s first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium. Speak
CeriBell Inc (CBLL) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Market ...
CeriBell Inc (CBLL) reports impressive revenue growth and market expansion, despite facing increased operating expenses and litigation costs.
CeriBell Q1 Earnings Call Highlights
CeriBell (NASDAQ:CBLL) reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company’s strongest quarter of net new hospital additions since becoming public. On the company’s earnings call, Co-founder
CeriBell (CBLL) Q1 2026 Earnings Transcript
Earlier today, CeriBell, Inc. issued a press release announcing financial results for the quarter ended 03/31/2026. Beyond continued progress in penetrating our core seizure market, we delivered two major milestones that mark inflection points in the evolution of our platform.
CeriBell, Inc. (CBLL) Reports Q1 Loss, Beats Revenue Estimates
CeriBell, Inc. (CBLL) delivered earnings and revenue surprises of -32.48% and +1.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?